Mineralys Therapeutics MLYS
NASDAQ MLYS
$24.48 -1.15 (-4.49%)
At close: Sep 29, 2026 · 4:00 PM EDT

Mineralys Therapeutics (MLYS) Total Debt (2026)

Updated

Mineralys Therapeutics (MLYS) reported Total Debt of $97.62 million for Q2 2026.

Analysis

Mineralys Therapeutics (MLYS) Total Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 49.04 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 70.82 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 53.91 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 37.49 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -111.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 57.30 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 26.25 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 63.19 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Mineralys Therapeutics 2.26 Bn 2.26 Bn - 97.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.62 Mn
API Access

Mineralys Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=MLYS&period=max&api_key=YOUR_API_KEY